



FY2025 Q1 Earnings Results

FY2025 Q1 Earnings Results

Revenue

¥1,106.7B

Generic erosion was significant, but
consistent with company expectations

-3.7%

at Constant
Exchange Rate (CER)

-8.4%

at actual
exchange rates (AER)

Core Operating Profit

¥321.8B

-11.9% at CER and
-15.8% at AER.

Mainly impacted by generic erosion

Core Operating Profit Margin

29.1%

Reported Operating Profit


¥184.6B

+11.0% growth at AER.

Reflecting lower impairment and
restructuring expenses compared to
FY2024 Q1

FY2025 Q1 Earnings Results

Growth & Launch Products grew at +5.0% at CER and now account for 50% of total company revenue



No Change to FY2025 Full Year Outlook

Core Revenue

¥4,530.0B

Core Operating Profit

¥1,140.0B

Core EPS

¥485

Management Guidance at CER

Core Revenue

Broadly flat

Core Operating Profit

Broadly flat

Core EPS

Broadly flat

Progress in Late-Stage Pipeline



In July, announced **positive topline results** from Phase 3 studies investigating a **potential treatment** for narcolepsy type 1





This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2025 Q1 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating financial results in accordance with IFRS or Core (non-IFRS) financial measures for the current period using corresponding exchange rates in the same period of the previous fiscal year, except for the results of operations of subsidiaries in countries experiencing hyperinflation and for which IAS29, Financial Reporting in Hyperinflation Economies, is applied.

Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate ("CER") change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2025 Q1 investor presentation (available at <https://www.takeda.com/investors/financial-results/quarterly-results/>) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.